1.
Eur J Clin Microbiol Infect Dis
; 38(3): 423-426, 2019 Mar.
Article
in English
| MEDLINE
| ID: mdl-30443683
ABSTRACT
Clinicians sometimes use switching strategies based on regimens such as RAL + ABC/3TC or RPV + ABC/3TC in order to resolve tolerability or safety issues associated with conventional recommended first-line strategies. Despite the low genetic barrier of these regimens, high safety and efficacy rates have been reported in retrospective studies.
Subject(s)
Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , HIV-1/drug effects , Anti-HIV Agents/adverse effects , Anti-HIV Agents/economics , Antiretroviral Therapy, Highly Active/adverse effects , Antiretroviral Therapy, Highly Active/economics , Dideoxynucleosides/adverse effects , Dideoxynucleosides/pharmacology , Dideoxynucleosides/therapeutic use , Drug Combinations , Drug Resistance, Viral/genetics , Drug Substitution , HIV Infections/genetics , HIV Infections/virology , HIV-1/genetics , Humans , Lamivudine/adverse effects , Lamivudine/pharmacology , Lamivudine/therapeutic use , Raltegravir Potassium/adverse effects , Raltegravir Potassium/therapeutic use , Rilpivirine/adverse effects , Rilpivirine/therapeutic use , Treatment Outcome , Viral Load/drug effects
2.
